Literature DB >> 9224499

Regulation and function of the multidrug resistance genes in liver.

J A Silverman1, S S Thorgeirsson.   

Abstract

The P-glycoproteins are integral membrane proteins that function as ATP-dependent transporters. The multidrug resistance genes which encode P-gp comprise a small gene family, with 2 members in humans and 3 in rodents. The P-gp encoded by the mdr1 gene functions as a drug efflux pump to remove drugs from cells and may serve as a barrier to protect cells from cytotoxic agents. In normal tissues, P-gp is localized on the luminal surface of transporting epithelia in the liver, kidney, small intestine, testes, and blood-brain barrier. Transient exposure to drugs transcriptionally increases the level of expression of the mdr1 genes, however, the cellular pathways critical to this regulation are yet unknown. This observation may have some implications on the level of expression in tumors and response to chemotherapy. Examination of the basal level of MDR expression in tumors may not be a reliable predictor of the effect of P-gp on chemotherapy. Induction of MDR transcription by drugs may further impede the effectiveness of anti-cancer agents. This is most obvious for drugs which are substrates for P-gp transport, however, it also applies significantly to compounds which are not themselves substrates but affect the response to other drugs simultaneously or subsequently administered. A clear understanding of the mechanisms that regulate basal and drug-induced mdr transcription will facilitate development of novel agents which circumvent this obstacle or permit targeted modification of mdr expression. Expressed on the bile canalicular surface of the liver, P-gps represent the first ATP-dependent biliary transporters to be characterized. The P-gp encoded by mdr2 is the major form of P-gp expressed in normal liver and transports phospholipids into bile. A defect in this protein leads to severe liver disease caused by chronic inflammation of the biliary system that results from high concentrations of free bile salts. The cellular origin and molecular basis of the ensuing liver tumors in these mice are unclear. It is possible that the chronic damage to the biliary ductules causes an increased growth rate of the surrounding cells, including putative stem cells in the liver. Thus, these mice may serve as a model for carcinogenesis in which the liver is under constant promotion placing the proliferating cells at increased risk to further genetic alterations or expansion of preexisting, but normally quiescent, mutations. Mdr2-deficient animals may also provide a model for human chronic inflammatory liver disease. Clearly, these exciting results indicate that further characterization of the P-gps as normal physiologic canalicular membrane transporters is necessary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9224499

Source DB:  PubMed          Journal:  Prog Liver Dis        ISSN: 1060-913X


  11 in total

1.  Quantitative evaluation of capacity-limited hepatobiliary transport based on hepatocellular diffusion model by MULTI(FEM).

Authors:  M Higashimori; K Yamaoka; S Fujitani; T Nakagawa
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

Review 2.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

4.  Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1.

Authors:  P C Brown; J A Silverman
Journal:  Nucleic Acids Res       Date:  1996-08-15       Impact factor: 16.971

Review 5.  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Mariko Matsumoto; Tsutomu Urano; Ryuichi Hasegawa
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Phospholipid alterations in hepatocyte membranes and transporter protein changes in cholestatic rat model.

Authors:  H Hyogo; S Tazuma; T Nishioka; H Ochi; A Yamaguchi; Y Numata; K Kanno; M Sakomoto; Y Asamoto; K Tsuboi; K Nakai; S Yasumiba; Y Sunami; G Kajiyama
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

7.  Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.

Authors:  Y Soini; N Virkajärvi; H Raunio; P Pääkkö
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

8.  Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.

Authors:  Tineke Kok; Vincent W Bloks; Henk Wolters; Rick Havinga; Peter L M Jansen; Bart Staels; Folkert Kuipers
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

9.  Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Josiah Cox; Steven Weinman
Journal:  Hepat Oncol       Date:  2016-01-01

Review 10.  Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations.

Authors:  M Trauner
Journal:  Yale J Biol Med       Date:  1997 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.